Curcumin, anti-oxidant, and pioglitazone therapy with inclusion of vitamin e in non-alcoholic fatty liver disease-a randomized open label placebo controlled clinical prospective trial (captive)

Basu, Patrick; Mittimanj, K.; Shah, Niraj James; Siriki, Ravi; Rahaman, K.; NirajAtluri,; Brown, R. Jr

doi:10.1016/j.jceh.2013.03.054

Cited by 3 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the initial 13,900 publications that were obtained by electronic search (5,535 duplicates), 8,355 were excluded because they were unrelated to present meta‐analysis according to our inclusion criteria. After reading the full text of the remaining 10 studies, four studies were also excluded for the following reasons: two studies did not report data on liver enzymes (Basu et al, ; Jazayeri‐Tehrani et al, ), one study was a duplicate report (Ghaffari, Rafraf, Navekar, & Asghari‐Jafarabadi, ), and one study was published as protocol (Jazayeri‐Tehrani et al, ). Finally, six eligible RCTs (Chirapongsathorn et al, ; Jarahzadeh & Hosain, ; Moradi et al, ; Navekar et al, ; Panahi et al, ; Rahmani et al, ) were included in our analysis.…”

Section: Resultsmentioning

confidence: 99%

“…After reading the full text of the remaining 10 studies, four studies were also excluded for the following reasons: two studies did not report data on liver enzymes (Basu et al, 2013;Jazayeri-Tehrani et al, 2018), one study was a duplicate report (Ghaffari, Rafraf, Navekar, & Asghari-Jafarabadi, 2018), and one study was published as protocol (Jazayeri-Tehrani et al, 2017). Finally, six eligible RCTs (Chirapongsathorn et al, 2012;Jarahzadeh & Hosain, 2017;Moradi et al, 2016;Navekar et al, 2017;Panahi et al, 2017;Rahmani et al, 2016) were included in our analysis.…”

Section: Identification and Selection Of Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Does turmeric/curcumin supplementation improve serum alanine aminotransferase and aspartate aminotransferase levels in patients with nonalcoholic fatty liver disease? A systematic review and meta‐analysis of randomized controlled trials

Goodarzi

Sabzian

Shishehbor

et al. 2019

Phytotherapy Research

View full text Add to dashboard Cite

We performed a meta‐analysis to evaluate the efficacy of turmeric/curcumin supplementation on serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in patients with nonalcoholic fatty liver disease (NAFLD). We searched PubMed, Scopus, Cochrane Library, ISI Web of Science, and Google Scholar up to November 20, 2018. Studies that examined the effect of turmeric/curcumin on serum concentrations of ALT and AST among patients with NAFLD were included. The mean difference and standard deviation (SD) of changes in ALT and AST between intervention and control groups were used as effect size for the meta‐analysis. A total of six randomized controlled trials (RCTs) were eligible for meta‐analysis. Results from pooled analysis revealed that turmeric/curcumin supplementation reduced ALT (MD: −7.31 UL/L, 95% CI [−13.16, −1.47], p = 0.014) and AST (MD: −4.68 UL/L, 95% CI [−8.75 −0.60], p = 0.026). When RCTs stratified on the basis of their treatment duration, the significant reduction in serum concentrations of ALT and AST was observed only in studies lasting less than 12 weeks. This review suggests that turmeric/curcumin might have a favorable effect on serum concentrations of ALT and AST in patients with NAFLD. However, further clinical trials are needed to confirm these findings.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Identification and Selection Of Studiesmentioning

confidence: 99%

Does turmeric/curcumin supplementation improve serum alanine aminotransferase and aspartate aminotransferase levels in patients with nonalcoholic fatty liver disease? A systematic review and meta‐analysis of randomized controlled trials

Goodarzi

Sabzian

Shishehbor

et al. 2019

Phytotherapy Research

View full text Add to dashboard Cite

show abstract

“…For the HCD/Cur system, the stable binding model from docking was used as the starting structure of MD simulation. In our modeling, the AutoDock Tools package (version 1.5.6) and AutoDock Vina (version 1.1.2) [6] were used to perform docking studies [7]. In docking simulation, Cur was used as a ligand while HCD was used as a receptor.…”

Section: Methodsmentioning

confidence: 99%

“…Curcumin (1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) is a hydrophobic polyphenol derived from the rhizome of turmeric (Curcuma longa), as shown in Figure 1A. Curcumin possesses anti-inflammatory [4], anti-arthritic [5], antioxidant [6], anticancer [7], anti-ischemic [8], and antiproliferative activities [9]. Preclinical and clinical studies also indicate its potential therapeutic value for most chronic inflammation such as lung inflammation, bowel syndrome, and arthritis.…”

Section: Introductionmentioning

confidence: 99%

Molecular Interactions for the Curcumin-Polymer Complex with Enhanced Anti-Inflammatory Effects

Liu

Bian

et al. 2019

Pharmaceutics

View full text Add to dashboard Cite

The molecular interactions between compound and polymeric carriers are expected to highly contribute to high drug load and good physical stability of solid dispersions. In this study, a series of amorphous solid dispersions (ASD) of Curcumin (Cur) were prepared with different polymers by the solvent evaporation method. With the carrier polyvinylpyrrolidone (PVP), the amorphous solid dispersion system exhibits a better solubility and stability than that with poloxamers and HP-β-CD due to the strong drug-polymer interaction. The drug/polymer interaction and their binding sites were investigated by combined experimental (XRD, DSC, FTIR, SEM, Raman, and 1H-NMR) and molecular dynamics simulation techniques. The Curcumin ASD demonstrated enhanced bioavailability by 11-fold and improved anti-inflammatory activities by the decrease in cytokine production (MMP-9, IL-1β, IL-6, VEGF, MIP-2, and TNF-α) compared to the raw Curcumin. The integration of experimental and modeling techniques is a powerful tool for the rational design of formulation development.

show abstract

Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis

Komolafe

Buzzetti

Linden

et al. 2021

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

show abstract

Curcumin, anti-oxidant, and pioglitazone therapy with inclusion of vitamin e in non-alcoholic fatty liver disease-a randomized open label placebo controlled clinical prospective trial (captive)

Cited by 3 publications

References 0 publications

Does turmeric/curcumin supplementation improve serum alanine aminotransferase and aspartate aminotransferase levels in patients with nonalcoholic fatty liver disease? A systematic review and meta‐analysis of randomized controlled trials

Does turmeric/curcumin supplementation improve serum alanine aminotransferase and aspartate aminotransferase levels in patients with nonalcoholic fatty liver disease? A systematic review and meta‐analysis of randomized controlled trials

Molecular Interactions for the Curcumin-Polymer Complex with Enhanced Anti-Inflammatory Effects

Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis

Contact Info

Product

Resources

About